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Background: The evidences of therapy with drug-eluting stents (DES) in the left main coronary artery are mostly based on trials performed with 
first-generation DES. There is paucity of data with long-term follow up with second-generation DES in this setting.
Methods: The ESTROFA-LM is a multicenter retrospective registry collecting consecutive patients treated in unprotected left main coronary artery 
with a first-generation DES (paclitaxel-eluting stent, PES) and with a second-generation DES (everolimus-eluting stent, EES).
Results: The registry is still open and 16 centers have provided data so far. Up to now 414 pts have been included, 212 treated with PES and 202 
treated with EES. The clinical and angiographic characteristics were comparable in both groups without significant differences except for the use of 
IVUS (28.3% with PES vs. 38.6% with EES; p=0.03). The 3 years survival free of death and infarction was 83.4% for PES and 87% for EES (p=0.4). 
Definite or probable thrombosis was 1.8% for PES and 0.9% for EES (p=0.6). At 3 years the incidence of target lesion revascularization was 5.2% 
for PES and 3.6% for EES (p=0.5).The use of 2 stents-technique (HR 3.2, 95% CI 1.1-8.2;p=0.03), previous PCI (HR 3, 95% CI 1.2-8.6; p=0.03) and 
previous MI (HR 2.4, 95% CI1.08-4.5;p=0.04) were independent predictors for events. The use of IVUS was associated with less events in univariant 
but not in multivariant analysis. The stent type was not predictor.
Conclusions: The results of this multicenter registry suggest a comparable safety and efficacy at 3 years for PES and EES in the treatment of the 
left main coronary artery, however a trend for a lower thrombosis and TLR incidences was observed with EES. The use of 2 stents was independently 
associated with a worse outcome. A large additional enrollment is expected in following months.
